Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NGNE Stock Forecast 2026-2027
$26.49
Current Price
$418.59M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NGNE Price Targets
+579.5%
To High Target of $180.00
+160.5%
To Median Target of $69.00
+73.7%
To Low Target of $46.00
NGNE Price Momentum
+1.3%
1 Week Change
-13.9%
1 Month Change
+33.0%
1 Year Change
+28.6%
Year-to-Date Change
-28.9%
From 52W High of $37.27
+80.8%
From 52W Low of $14.65
📊 TOP ANALYST CALLS
Did NGNE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neurogene is one of their latest high-conviction picks.
Latest NGNE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NGNE has a bullish consensus with a median price target of $69.00 (ranging from $46.00 to $180.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $26.49, the median forecast implies a 160.5% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 579.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NGNE Analyst Ratings
9
Buy
0
Hold
0
Sell
NGNE Price Target Range
Low
$46.00
Average
$69.00
High
$180.00
Current: $26.49
Latest NGNE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NGNE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $180.00 |
| Feb 27, 2026 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Jan 26, 2026 | LifeSci Capital | Outperform | Initiates | $N/A | |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 31, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 9, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 17, 2025 | Craig-Hallum | Buy | Initiates | $N/A | |
| Jun 12, 2025 | BMO Capital | Outperform | Maintains | $N/A | |
| May 20, 2025 | BMO Capital | Outperform | Maintains | $N/A | |
| May 16, 2025 | Baird | Neutral | Downgrade | $N/A | |
| May 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 14, 2025 | BMO Capital | Outperform | Maintains | $N/A | |
| Mar 25, 2025 | Baird | Outperform | Maintains | $N/A | |
| Mar 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 20, 2024 | BMO Capital | Outperform | Maintains | $N/A | |
| Nov 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 12, 2024 | Stifel | Buy | Maintains | $N/A | |
| Nov 12, 2024 | BMO Capital | Outperform | Maintains | $N/A |
Neurogene Inc. (NGNE) Competitors
The following stocks are similar to Neurogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurogene Inc. (NGNE) Financial Data
Neurogene Inc. has a market capitalization of $418.59M with a P/E ratio of -6.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.3%.
Valuation Metrics
Market Cap
$418.59M
Enterprise Value
$184.54M
P/E Ratio
-6.2x
PEG Ratio
-0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+58.1%
Current Ratio
13.1x
Debt/Equity
3.8x
ROE
-37.3%
ROA
-23.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neurogene Inc. (NGNE) Business Model
About Neurogene Inc.
What They Do
Develops gene therapies for rare neurological diseases.
Business Model
Neurogene Inc. operates as a clinical-stage biotechnology company that focuses on creating genetic medicines specifically for rare neurological conditions. The company generates revenue by developing its proprietary gene therapies, such as NGN-401 for Rett syndrome, which is currently undergoing clinical trials and has received various FDA designations that may facilitate faster market access.
Additional Information
Founded in 2018 and based in New York, Neurogene is dedicated to addressing significant unmet medical needs in the field of rare neurological disorders. Its innovative approach emphasizes safety and effectiveness in gene therapy, leveraging advanced technologies for gene delivery and regulation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Dr. Rachel L. McMinn Ph.D.
Country
United States
IPO Year
2023
Website
www.neurogene.comNeurogene Inc. (NGNE) Latest News & Analysis
Latest News
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) announced the approval of non-qualified stock options for 17,045 shares to two new employees, effective June 1, 2026, by its Compensation Committee.
Why It Matters
The grant of stock options to new employees indicates confidence in the company's future growth, potentially enhancing employee motivation and aligning interests with shareholders.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) reported Q1 2026 results, noting strong momentum for its Rett syndrome treatment, NGN-401, with about 90% of participants dosed in the Embolden™ trial.
Why It Matters
Neurogene's progress in treating Rett syndrome and strong dosing momentum for NGN-401 could boost investor confidence, indicating potential market success and future revenue growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) presented data at the ASGCT Annual Meeting supporting the ICV route for delivering gene therapies for CNS disorders, indicating potential advancements in treatment methods.
Why It Matters
Neurogene's positive data on ICV delivery for gene therapies could enhance treatment options for CNS disorders, potentially boosting its market value and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) will present a poster on the intracerebroventricular (ICV) administration method for CNS gene therapy, highlighting its efficacy in treating rare neurological diseases.
Why It Matters
Neurogene's poster presentation could highlight advancements in CNS gene therapy, potentially boosting investor confidence and impacting stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. appointed Christy Shafer as Chief Commercial Officer and Christine Mikail to its Board of Directors, enhancing its leadership in genetic medicines for rare neurological diseases.
Why It Matters
Neurogene's leadership changes signal a strategic focus on commercial growth, potentially enhancing its market position and investor confidence in its genetic therapies for rare diseases.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Neurogene Inc. (Nasdaq: NGNE) reported 2025 financial results, completed enrollment in the Embolden trial, and received Breakthrough Therapy designation for its drug NGN-40.
Why It Matters
Neurogene's completion of trial enrollment and Breakthrough Therapy designation for NGN-40 could accelerate its product development timeline, potentially increasing market value and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NGNE Stock
What is Neurogene Inc.'s (NGNE) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Neurogene Inc. (NGNE) has a median price target of $69.00. The highest price target is $180.00 and the lowest is $46.00.
Is NGNE stock a good investment in 2026?
According to current analyst ratings, NGNE has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NGNE stock?
Wall Street analysts predict NGNE stock could reach $69.00 in the next 12 months. This represents a 160.5% increase from the current price of $26.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurogene Inc.'s business model?
Neurogene Inc. operates as a clinical-stage biotechnology company that focuses on creating genetic medicines specifically for rare neurological conditions. The company generates revenue by developing its proprietary gene therapies, such as NGN-401 for Rett syndrome, which is currently undergoing clinical trials and has received various FDA designations that may facilitate faster market access.
What is the highest forecasted price for NGNE Neurogene Inc.?
The highest price target for NGNE is $180.00 from Whitney Ijem at Canaccord Genuity, which represents a 579.5% increase from the current price of $26.49.
What is the lowest forecasted price for NGNE Neurogene Inc.?
The lowest price target for NGNE is $46.00 from at , which represents a 73.7% increase from the current price of $26.49.
What is the overall NGNE consensus from analysts for Neurogene Inc.?
The overall analyst consensus for NGNE is bullish. Out of 2 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $69.00.
How accurate are NGNE stock price projections?
Stock price projections, including those for Neurogene Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 1:18 PM UTC